ClinicalTrials.gg
Enrolling by invitationNCT07286201ENHANCE IIUpdated Jun 25, 2026

Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)

An interventional study of OCEAN and Steroid-eluting sinus stent in Chronic Rhinosinusitis (CRS) and Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, sponsored by Polyganics BV. Enrolling by invitation at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Polyganics BV · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Planned enrollment
26th of 71
110 · median 60
Started
2026
with 6 others
No phase
14 of 83
5 open now
Primary completion
2027-03
later than 8 of 19 live
Registered
78th of 83
by date

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 26th largest by planned enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 78th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and effectiveness of OCEAN as an adjunct aid in wound healing after nasal/sinus surgery and to demonstrate that OCEAN is non-inferior compared to a steroid-eluting sinus stent.

Read the detailed description

A multicenter, randomized, single-blinded, controlled, intra-patient non-inferiority study enrolling 110 subjects at up to 13 sites in the United States.

03

Conditions studied

  • Chronic Rhinosinusitis (CRS)
  • Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Keywords

  • Nasal Packing
  • Mometasone Furoate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 years or older
  2. Subject is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitus with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP) and is indicated for bilateral complete ethmoidectomy (anterior and posterior ethmoidectomy) at a minimum. Additional sinuses may be operated on at the surgeon's discretion.
  3. Subject is willing and able to provide .
  4. Subject is willing and able to comply with the plan requirements.
  5. Subjects with a pre-operative Lund-MacKay stage of 6 (≥3 per nostril).
  6. Subject with a pre-operative Lund-Mackay stage side-to-side difference ≤ 2.
  7. Subject of is not pregnant and agrees to not become pregnant during the course of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months.
  2. Subject with an underlying systemic disorders known to affect the nose (e.g., Wegener's granulomatosis, sarcoidosis, Churg-Strauss syndrome, or other systemic vasculitides).
  3. Subject with any bleeding disorder or use of medication increasing bleeding risk, except low-dose aspirin.
  4. Subject with a known or suspected allergy to device components.
  5. Subject with known hemophilia.
  6. Subject with insulin dependent diabetes.
  7. Subject with an oral dependent condition.
  8. Subject with glaucoma, ocular hypertension, posterior subcapsular cataracts.
  9. Subject with a (previous) diagnosis of Samter's Triad (AERD).
  10. Subject that requires nasal ointments or creams at time of device placement.
  11. Subject with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data.
  12. Subject with plans to (or otherwise anticipate the need to) undergo an ENT procedure within the 90-day study follow-up.
  13. Subject participating in another clinical research study (within 30 days prior to screening up to 90 days post-operative).
  14. Subject that used any form of biologics within 90 days prior to sinus surgery and during follow-up to day 25.
  15. Subject that used any form of corticosteroid within 2 weeks prior to sinus surgery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    OCEAN

    Application after nasal/sinus surgery

    Device: OCEAN

  • Active comparator
    Steroid-eluting Sinus Stent

    Application after nasal/sinus surgery

    Device: Steroid-eluting sinus stent

Interventions

  • DeviceOCEAN

    Biodegradable nasal dressing applied after sinus/nasal surgery

  • DeviceSteroid-eluting sinus stent

    Applied after sinus/nasal surgery

06

What researchers measure

Primary outcomes

  1. Rate of Serious Adverse Events

    Rate of serious adverse events related to the use of OCEAN bioresorbable nasal dressing.

    Time frame: Up to Day 25

  2. Endoscopic Assessment

    Endoscopic assessment of wound healing to compare test-treated and control-treated cavities.

    Time frame: Day 25

Secondary outcomes

  1. Rate of Adverse Events

    Assessment of all adverse events.

    Time frame: Up to Day 90

  2. Endoscopic Evaluation of Sinonasal Cavities

    Endoscopic evaluation of sinonasal cavities for to evaluate wound healing.

    Time frame: Days 25 and 90

  3. Rate of post-operative interventions

    Rate of post-operative interventions, including surgical intervention to separate adhesions, and/or oral steroid intervention, and/or biologics.

    Time frame: Up to Day 25 and Day 90

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 16, 2025
StartActual
Mar 19, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07286201
Lead sponsor
Polyganics BV
Collaborators
NAMSA
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Mar 19, 2026
Primary completion
Mar 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion